⚡️💥🇺🇸#SRNE
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary Off-the-Shelf Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma